专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11857522B2 Compositions containing tucaresol or its analogs 有权
公开(公告)号：US11857522B2
公开(公告)日：2024-01-02
申请号：US17170058
申请日：2021-02-08
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Ramon Mohanlal , Lan Huang , George Kenneth Lloyd
IPC分类号： A61K31/192 , A61P35/00 , A61K31/496 , A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： A61K31/192 , A61K31/496 , A61K39/3955 , A61P35/00 , C07K16/2818 , C07K16/2827 , A61K2039/505
摘要： Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

2. 发明公开

US20230181605A1 TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY 审中-公开
公开(公告)号：US20230181605A1
公开(公告)日：2023-06-15
申请号：US17923189
申请日：2021-04-30
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Ramon Mohanlal , Lan Huang
IPC分类号： A61K31/663 , A61P35/00 , A61P25/00 , A61K31/497 , A61K39/395
CPC分类号： A61K31/663 , A61P35/00 , A61P25/00 , A61K31/497 , A61K39/3955
摘要： Disclosed herein are composition and methods of treating a condition where enhanced immunogenicity is desired. Some embodiments disclosed herein relate to compositions comprising a T-cell activator and/or proliferator, one or more immune checkpoint inhibitor, and a FPPS inhibitor. Some embodiments relate to methods of treating cancer by co-administering plinabulin, one or more immune checkpoint inhibitor, and a FPPS inhibitor to a subject in need thereof.

3. 发明申请

US20220169635A1 PLINABULIN COMPOSITIONS 有权
公开(公告)号：US20220169635A1
公开(公告)日：2022-06-02
申请号：US17675453
申请日：2022-02-18
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Lan Huang , Aniruddh Singh
IPC分类号： C07D403/06 , B01D9/00
摘要： Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

4. 发明申请

US20220143013A1 COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA 有权
公开(公告)号：US20220143013A1
公开(公告)日：2022-05-12
申请号：US17581174
申请日：2022-01-21
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Lan Huang , George Kenneth Lloyd , Ramon Mohanlal
IPC分类号： A61K31/496 , A61K31/337 , A61K31/4745 , A61P35/00 , A61K31/675 , A61K45/06 , A61K31/704 , A61P39/00 , A61K33/243 , A61K31/351 , A61K31/664 , A61N5/10
摘要： Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

5. 发明授权

US10550104B2 Plinabulin compositions 有权
公开(公告)号：US10550104B2
公开(公告)日：2020-02-04
申请号：US16212386
申请日：2018-12-06
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Lan Huang , Aniruddh Singh
IPC分类号： C07D403/06 , B01D9/00
摘要： Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

6. 发明授权

US12024501B2 Plinabulin compositions 有权
公开(公告)号：US12024501B2
公开(公告)日：2024-07-02
申请号：US17675453
申请日：2022-02-18
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Lan Huang , Aniruddh Singh
IPC分类号： C07D403/06 , B01D9/00
CPC分类号： C07D403/06 , B01D9/0045 , B01D9/0054 , B01D9/0063 , B01D2009/0086 , C07B2200/13
摘要： Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

7. 发明申请

US20220387365A1 TUCARESOL DERIVATIVES AND USES THEREOF 有权
公开(公告)号：US20220387365A1
公开(公告)日：2022-12-08
申请号：US17775851
申请日：2020-11-09
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Chengjiang He , Lan Huang , James R. Tonra
IPC分类号： A61K31/198 , A61K39/395 , A61K45/06 , A61K31/496 , A61P35/00 , A61K31/405 , A61K31/4172 , A61K31/7034 , A61K31/235 , A61K31/24 , C07C235/84 , C07D209/20 , C07C323/59 , C07D233/64 , C07H15/18 , C07C69/94 , C07C251/48
摘要： Disclosed herein are tucaresol derivative compound and composition containing the same. Also disclosed herein are methods of enhancing immune response in a subject by administering the tucaresol derivative compound or by co-administering the tucaresol derivative compound and one or more additional agents. Also disclosed herein are use of the tucaresol derivative compound and composition containing the same in the manufacture of a medicament for treating cancer or enhancing immune response in a subject.

8. 发明授权

US10668063B2 Method of treating cancer associated with a RAS mutation 审中-公开
公开(公告)号：US10668063B2
公开(公告)日：2020-06-02
申请号：US16290765
申请日：2019-03-01
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Lan Huang
IPC分类号： A61K31/496 , A61K45/06 , A61P35/00 , A61K31/337 , A61K31/4745
摘要： Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.

9. 发明授权

US10155748B2 Plinabulin compositions 有权
公开(公告)号：US10155748B2
公开(公告)日：2018-12-18
申请号：US15741635
申请日：2016-07-11
申请人： BeyondSpring Pharmaceuticals, Inc.
发明人： Lan Huang , Aniruddh Singh
IPC分类号： C07D403/06 , B01D9/00
摘要： Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

10. 发明申请

US20160250209A1 CANCER TREATMENT WITH COMBINATION OF PLINABULIN AND TAXANE 审中-公开
标题翻译：癌症治疗与联合治疗和TAXANE组合
公开(公告)号：US20160250209A1
公开(公告)日：2016-09-01
申请号：US15028376
申请日：2013-10-11
申请人： BEYONDSPRING PHARMACEUTICALS, INC.
发明人： Lan Huang
IPC分类号： A61K31/496 , A61K31/337
CPC分类号： A61K31/496 , A61K31/337 , A61K2300/00
摘要： This invention provides a novel cancer treatment method in which plinabulin (t-butyl-dehydrophenylahistin or NPI-2358) and a taxane compound (such as docetaxel) are used in combination. Our study has shown that the optimum combination of injecting plinabulin after taxane compound has unexpected enhanced efficacy in large tumor populations in animal model and in NSCLC cancer patients compared to taxane compound treatment alone. In addition, this optimum combination can achieve unexpected safety effect in lowering unbearable side effects of taxane compound, including decreasing its neutropenia rates at all grades and decreasing G-CSF use in cancer patients.
摘要翻译：本发明提供了一种新的癌症治疗方法，其中组合使用了普拉宁（叔丁基 - 脱氢亚苯基激素或NPI-2358）和紫杉烷化合物（如多西紫杉醇）。我们的研究表明，与紫杉烷类化合物治疗相比，在紫杉烷化合物中注射普拉文灵的最佳组合在动物模型和NSCLC癌症患者的大肿瘤群体中具有出人意料的增强的功效。此外，这种最佳组合可以降低紫杉类化合物难以忍受的副作用，包括降低其各种级别的中性粒细胞减少率，降低癌症患者的G-CSF用量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式